Washington D.C. – The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over 1000 community-based participants from throughout the US compared the results of blood and digital biomarkers with brain amyloid PET scans or cerebrospinal fluid assays. The study revealed a...
Latest News
Odense, Denmark – Over the past two decades, immunotherapy – utilizing the body’s own immune system to combat illness – has emerged as a groundbreaking treatment for various types of cancer. The body’s own T-cells possess a remarkable capacity to identify and fight a wide range of cancers. Regrettably, cancer...
Alexander disease is a progressive and rare neurological disorder with no cure or standard course of treatment. But a new study led by researchers at the University of Wisconsin–Madison involving a rat model of the disease offers a potential treatment for the typically fatal condition. It’s a significant step in...
MDUK is delighted to bring you the news that a highly complex, innovative gene therapy is to become available on the NHS in England for the treatment of spinal muscular atrophy (SMA) Type 1. Babies born with SMA Type 1, the most common form of the condition, are unable to...
Garden City, NY — ProPhase Labs Inc. (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. Ted Karkus, CEO of ProPhase Labs,...
Patients with moderate or severe hemophilia A can benefit from early prophylactic antihemophilic factor (recombinant) (rAHF), according to an interim analysis presented at the 2021 British Society for Haematology annual meeting. The international AHEAD study is a 6 year non-interventional, prospective trial looking at joint health in patients receiving prophylactic...
The use of intravenous immunoglobulin (IVIG) may provide benefit against infections in subgroups of patients with multiple myeloma (MM), according to a retrospective, single-center crossover study that compared rates of infection in patients with MM during observation compared with those receiving IVIG. The study results were published in Clinical Lymphoma, Myeloma...
LEIDEN, Netherlands & CAMBRIDGE, Mass. — ProQR Therapeutics NV, a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced a collaboration with the Rett Syndrome Research Trust (RSRT) that will focus on the design and development of editing oligonucleotides...
LEIDEN, Netherlands & CAMBRIDGE, Mass. – ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The companies will use ProQR’s...
LEIDEN, Netherlands & CAMBRIDGE, Mass. – ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and...